Massachusetts Xylazine Commission Drafts Final Report, Plans March Vote on Recommendations

BOSTON — February 9, 2026 — Massachusetts xylazine commission reviews draft final report and targets March 9 vote. The Special Commission on the Public Health Effects of Xylazine, co-chaired by Representative Mindy Dohm, met February 9 to walk through a draft final report organized around four working groups covering enforcement, outreach, treatment, and education, with a statutory submission deadline of March 30, 2026. The draft's primary recommendation rejects raising xylazine's existing Massachusetts Schedule 6 classification in favor of expanded harm reduction, drug checking, and toxicology surveillance, with any additional criminal penalties to be limited to illicit production and distribution rather than personal possession. Commissioner Undersecretary Angela Davis pressed for fire personnel to be included in all first-responder definitions, Senator John Keenan called for real-time alert systems for ambulance and law enforcement personnel citing meetings in Quincy, and Commissioner Ernie Gates flagged that many pharmacists and nurses remain unaware xylazine is a problem. Dohm proposed adding a recommendation that the Department of Public Health establish a standing task force on emerging drug supply threats, arguing the commission's work should produce a mechanism durable enough to address the next contaminant after xylazine.